Notice2025-10918
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 114 (Monday, June 16, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 114 (Monday, June 16, 2025)]
[Notices]
[Pages 25348-25349]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-10918]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Wade Green at 301-761-7505, or
[[Page 25349]]
<a href="/cdn-cgi/l/email-protection#32455356571c554057575c725c5b5a1c555d44"><span class="__cf_email__" data-cfemail="aaddcbcecf84cdd8cfcfc4eac4c3c284cdc5dc">[email protected]</span></a>. Information may be obtained by communicating with
the Technology Transfer and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301-496-2644. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Broadly Neutralizing Influenza Hemagglutinin Stem-Directed Antibodies
Description of Technology
In 2023, the World Health Organization (WHO) reported roughly 3 to
5 million cases of severe influenza worldwide, resulting in
approximately 290,000 to 650,000 deaths. Given the high disease burden,
the needs for both prophylactic and therapeutic influenza strategies
remain significant. However, current treatments for influenza are
susceptible to resistance and are useful for only a limited post-
infection period.
The highly conserved epitopes in the stem region of the influenza
hemagglutinin (HA) protein are ideal targets for new vaccines, as they
elicit broadly neutralizing antibodies. In light of this, researchers
at the National Institute of Allergy and Infectious Diseases (NIAID)
cloned and expressed HA stem-specific monoclonal antibodies (mAbs) from
B cells isolated from human participants in influenza vaccine clinical
trials. Four mAbs exhibited particularly potent neutralizing profiles
against H1N1 strains, three exhibited very strong neutralization
profiles against H3N2 strains, and two exhibited a good neutralization
profile across all subtypes tested. These mAbs may help to
substantially reduce global influenza disease burden given their
potential to become effective therapeutic and prophylactic agents
against a broad range of H1N1 and H3N2 influenza strains.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Prophylactic or therapeutic strategies against influenza
infection
Competitive Advantages:
<bullet> Greater neutralization potency against H1N1 and H3N2 strains
than observed for other high-profile candidates tested in phase II
clinical trials
Developmental Stage: Preclinical.
Publications:
<bullet> Andrews SF, et al. An influenza H1 hemagglutinin stem-only
immunogen elicits a broadly cross-reactive B cell response in humans.
Sci. Transl. Med. 2023;15:eade4976.
<bullet> Mantus GE, et al. Vaccination with different group 2 influenza
subtypes alters epitope targeting and breadth of hemagglutinin stem-
specific human B cells. Sci. Transl. Med. 2025;17:eadr8373.
Inventors: Sarah Andrews (NIAID), Grace Mantus (NIAID), Ankita
Chopde (NIAID), Adrian Creanga (NIAID), Rebecca Gillespie (NIAID);
Masaru Kanekiyo (NIAID); Lauren Cominksy (former NIAID; UPenn); Julie
Raab (former NIAID; UColorado)
Intellectual Property: HHS Reference No. E-026-2024; Provisional
Patent Application No.: 63/605,374, filed on December 1, 2023, and PCT
Patent Application No. PCT/US2024/057131, filed on November 22, 2024.
Licensing Contact: To license this technology, please contact Wade
Green at 301-761-7505, or <a href="/cdn-cgi/l/email-protection#f483959091da938691919ab49a9d9cda939b82"><span class="__cf_email__" data-cfemail="b1c6d0d5d49fd6c3d4d4dff1dfd8d99fd6dec7">[email protected]</span></a>, and reference E-026-2024.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Wade Green at 301-761-7505, or
<a href="/cdn-cgi/l/email-protection#04736560612a637661616a446a6d6c2a636b72"><span class="__cf_email__" data-cfemail="087f696c6d266f7a6d6d6648666160266f677e">[email protected]</span></a>, and reference E-026-2024.
Dated: June 9, 2025.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2025-10918 Filed 6-13-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.